港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段

智通财经
Apr 14

智通财经APP获悉,再鼎医药(09688)涨超3%,截至发稿,涨3.36%,报16.9港元,成交额2719.25万港元。

消息面上,近日,再鼎医药官微宣布,公司与安进公司达成一项全球临床研究合作,旨在评估再鼎医药处于临床阶段的靶向delta样配体3(DLL3)的抗体药物偶联物(ADC)zocilurtatug pelitecan(zoci,前称ZL-1310)联合安进IMDELLTRA®(塔拉妥单抗),一款靶向DLL3的双特异性T细胞衔接器(BiTE®)疗法,用于治疗广泛期小细胞肺癌(ES-SCLC)患者。作为该合作协议的一部分,安进将申办一项全球1b期研究,评估zoci联合IMDELLTRA®在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权,并将向安进提供临床研究用药。

中金指出,再鼎医药于2025年底启动了Zoci针对2/3L SCLC的全球注册性III期临床,治疗组为含铂化疗进展后的2L患者以及Tarla治疗后的3L患者,对照组为化疗,共计划入组480人,主要临床终点为ORR和OS,公司认为若数据支持,将于2027年在美国提交加速上市申请。此外,公司也计划于1H26公布2L+SCLC颅内数据以及肺外NEC数据,2H26公布1L SCLC 1期联合数据(+PDL1±化疗),该行建议关注相关数据读出。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10